X
X
Total 393357 Results
| Label | Description | ILX | Version | Created CID | Modified Time | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Embryonic | A maturity quality inhering in an organism by virtue of the organism being in its early stages of development, prior to birth or hatching. | ILX:0103745 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Embryonic Caenorhabditis elegans | The whole period of embryogenesis, from the formation of an egg till its hatch. (C. elegans development: http://purl.org/obo/owl/WBls#WBls_0000003) | ILX:0103746 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Embryonic cat | A cat in its early stages of development, prior to birth. | ILX:0103747 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Embryonic chimpanzee | A chimpanzee in its early stages of development, prior to birth. | ILX:0103748 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Embryonic dog | A dog in its early stages of development, prior to birth. | ILX:0103749 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Embryonic drosophila | A drosophila in its early stages of development, prior to hatching and beginning at the end of the fertilized egg stage. (Definition aligned with Drosophila development: http://purl.org/obo/owl/FBdv#FBdv_00005289) | ILX:0103750 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Embryonic ferret | A ferret in its early stages of development, prior to birth. | ILX:0103751 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Embryonic human | A human in its early stages of development, prior to birth. | ILX:0103752 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Embryonic mouse | A mouse in its early stages of development, prior to birth. | ILX:0103753 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Embryonic rabbit | A rabbit in its early stages of development, prior to birth. | ILX:0103754 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Embryonic rat | A rat in its early stages of development, prior to birth. | ILX:0103755 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Embryonic stem cell | A stem cell of embryonic origin. This is an in vitro cell type and may be removed in future releases. These cells are reportedly SSEA-4-positive, CD73-negative, and CD324-positive. | ILX:0103756 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Embryonic xenopus | A xenopus at any of the developmental stages from fertilization to feeding (Xenopus Anatomy Ontology: http://purl.org/obo/owl/XAO#XAO_1000012). | ILX:0103757 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Emedastine | Emedastine is an antihistamine used in eye drops to treat allergic conjunctivitis. (Wikipedia) Pharmacology: Emedastine is a relatively selective H1-receptor antagonist. Mechanism of action: Emedastine is a relatively selective, histamine H1 antagonist. In vitro examinations of emedastine's affinity for histamine receptors demonstrate relative selectivity for the H1 histamine receptor. In vivo studies have shown concentration-dependent inhibition of histamine-stimulated vascular permeability in the conjunctiva following topical ocular administration. Emedastine appears to be devoid of effects on adrenergic, dopaminergic and serotonin receptors. Drug type: Approved. Small Molecule. Drug category: Anti-Allergic Agents. Histamine H1 Antagonists | ILX:0103758 | 4 | scicrunch | 08/24/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Emmetropic Magnification | Emmetropic Magnification value (dimensionless). Zero length means the emmetropic magnification was not measured. | ILX:0103759 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Emotional regulation task | No definition submitted yet. | ILX:0103760 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Empty Image Density | Density of the image box area on the film that contains no image. | ILX:0103761 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| En Passant Bouton Quality | ILX:0103763 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Enalapril | One of the angiotensin-converting enzyme inhibitors that is used to treat hypertension. (PubChem) Pharmacology: Enalapril, an angiotensin-converting enzyme (ACE) inhibitor, is a prodrug which, when hydrolyzed by estarases to its active Enalaprilat, is used to treat hypertension and heart failure, to reduce proteinuria and renal disease in patients with nephropathies, and to prevent stroke, myocardial infarction, and cardiac death in high-risk patients. Enalapril and enalaprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Mechanism of action: Enalaprilat, the active metabolite of enalapril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Enalaprilat may also act on kininase II, an enzyme identical to ACE that degrades the vasodilator bradykinin. Drug type: Approved. Small Molecule. Drug category: Angiotensin-converting Enzyme Inhibitors. Antihypertensive Agents | ILX:0103764 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Encainide | All drug products containing encainide hydrochloride. Encainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack. The manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991. Pharmacology: Used to treat irregular heartbeats, encainide decreases excitability, conduction velocity, and automaticity as a result of slowed atrial, atrioventricular (AV) nodal, His-Purkinje, and intraventricular conduction. It causes a slight but significant prolongation of refractory periods in these tissues. The greatest effect is on the His-Purkinje system. Encainide decreases the rate of rise of the action potential without markedly affecting its duration. Mechanism of action: Encainide is a sodium channel blocker, binding to voltage gated sodium channels. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. Drug type: Approved. Small Molecule. Withdrawn. Drug category: Anti-Arrhythmia Agents. Antiarrhythmic Agents. Sodium channel blockers | ILX:0103765 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
About
Base community for the SciCrunch.org infrastructure
Contact Us
X